Ola E. Dahl
MD, DMSc
Dr Dahl received his medical education and academic degrees at the University of Oslo in Norway. He became a specialist, initially in general surgery and later in orthopaedic surgery. He has been involved in laboratory and clinical research for many years.
His discovery of the lung vasculature as thrombin-generating organs during bone surgery was a breakthrough in the understanding of the occurrence of posttraumatic systemic thromboembolic complications and vascular mortality as the major cause of deaths after major orthopeadic surgery.
He pioneered studies on out-of-hospital hypercoagulation and thromboembolism, which later has been confirmed by other scientific groups and become an industry design standard. Dr Dahl has been a frequent invited speaker, chaired and been on the boards of expert conferences at international conventions, and co-operated with colleagues worldwide and arranged conferences. He is one of the International opinion leaders within the field of thrombosis and haemostasis related to trauma and surgery. He has published numerous papers and abstracts on a variety of surgical issues. In particular, with emphasis on posttraumatic pathophysiology, bone cement cytotoxicity, bleeding, initiation and duration of hypercoagulability, its clinical consequences and several long term epidemiological studies on vascular outcomes following major surgical procedures.
Further, he has extensive experience with clinical development programs of new anticoagulant compounds and is a referee for several journals and a member of different societies. He is an Executive Director of International Surgical Thrombosis Forum (ISTF), a global Society bridging front knowledge
within thrombosis and haemostasis with skilled surgical experience. In addition, he is supervising PhD research fellows at Elverum Central hospital in Norway and attending the Thrombosis Research Institute in London, UK as Honorary Professor.
His discovery of the lung vasculature as thrombin-generating organs during bone surgery was a breakthrough in the understanding of the occurrence of posttraumatic systemic thromboembolic complications and vascular mortality as the major cause of deaths after major orthopeadic surgery.
He pioneered studies on out-of-hospital hypercoagulation and thromboembolism, which later has been confirmed by other scientific groups and become an industry design standard. Dr Dahl has been a frequent invited speaker, chaired and been on the boards of expert conferences at international conventions, and co-operated with colleagues worldwide and arranged conferences. He is one of the International opinion leaders within the field of thrombosis and haemostasis related to trauma and surgery. He has published numerous papers and abstracts on a variety of surgical issues. In particular, with emphasis on posttraumatic pathophysiology, bone cement cytotoxicity, bleeding, initiation and duration of hypercoagulability, its clinical consequences and several long term epidemiological studies on vascular outcomes following major surgical procedures.
Further, he has extensive experience with clinical development programs of new anticoagulant compounds and is a referee for several journals and a member of different societies. He is an Executive Director of International Surgical Thrombosis Forum (ISTF), a global Society bridging front knowledge
within thrombosis and haemostasis with skilled surgical experience. In addition, he is supervising PhD research fellows at Elverum Central hospital in Norway and attending the Thrombosis Research Institute in London, UK as Honorary Professor.
Meer informatie
